William Healy, MD
Pulmonary Disease · Augusta, GANPI 1992024608
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,771 of the $2,094 with a category attached, or 84.6%. 30 manufacturers reported payments, led by Harmony Biosciences LLC at 25.8% of the total. Reporting peaked in 2019 at $715 and has fallen 58.9% since, to $294 in 2025. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 56 payments — averaging $37.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$541
- ZOLL Respicardia, Inc.$267
- Jazz Pharmaceuticals Inc.$152
- Inspire Medical Systems, Inc.$144
- Abiomed$125
- Grifols Shared Services North America, Inc.$116
- plus $748 from 24 others
Across 11 payments — averaging $7638.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$84K
What the payments were for
- Food & beverage$1,77185%
- Education$32315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 8 | $541 |
| ZOLL Respicardia, Inc. | 1 | $267 |
| Jazz Pharmaceuticals Inc. | 4 | $152 |
| Inspire Medical Systems, Inc. | 1 | $144 |
| Abiomed | 1 | $125 |
| Grifols Shared Services North America, Inc. | 3 | $116 |
| Sanofi | 2 | $72 |
| Boehringer Ingelheim | 3 | $59 |
| Philips North America LLC | 3 | $51 |
| Inari Medical, Inc. | 1 | $51 |
| Resmed Corp | 3 | $45 |
| AstraZeneca | 3 | $44 |
| Novartis | 2 | $34 |
| Pulmonx Corporation | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| GSK | 2 | $32 |
| Nonin Medical, Inc. | 1 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
| Mylan Specialty L.p. | 2 | $28 |
| Insmed, Inc. | 2 | $27 |
| United Therapeutics Corporation | 1 | $22 |
| Shionogi Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Ambu Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Aurinia Pharma U.S., Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$267
- Inspire Upper Airway Stimulation System$144
- Impella$125
- SUNOSI$115
- Wakix$113
How this compares
$2,094 in reported general payments places this provider in the 35th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $52,282 |
| TezspireTezepelumab-Ekko | 13 | $50,253 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,358 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,589 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,438 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,318 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,977 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,024 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,254 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $1,721 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,390 |
| Montelukast Sodium | 43 | $423 |
| Furosemide | 11 | $25 |
| Prednisone | 15 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $44 | $61,71541 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $32 | $34,17775 claims |
| Boehringer IngelheimCombivent Respimat | $59 | $7,31815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Augusta
- Carmel JosephAugusta$43K
- Shaheen IslamAugusta$22K
- Varsha KulkarniAugusta$19K
- Scott PethkeAugusta$14K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.